KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Assets (2016 - 2025)

Historic Assets for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Acadia Pharmaceuticals' Assets rose 3622.83% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 3622.83%. This contributed to the annual value of $1.2 billion for FY2024, which is 5858.82% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Assets stood at $1.3 billion for Q3 2025, which was up 3622.83% from $1.2 billion recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Assets high stood at $1.3 billion for Q3 2025, and its period low was $587.8 million during Q4 2022.
  • Moreover, its 5-year median value for Assets was $724.4 million (2021), whereas its average is $822.5 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Assets crashed by 1733.67% in 2022, and later skyrocketed by 5858.82% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Assets stood at $700.1 million in 2021, then fell by 16.04% to $587.8 million in 2022, then grew by 27.41% to $749.0 million in 2023, then soared by 58.59% to $1.2 billion in 2024, then increased by 12.04% to $1.3 billion in 2025.
  • Its Assets was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.1 billion in Q1 2025.